Abstract:OBJECTIVE: Investigate the prevalence of stigma toward neuropsychiatric illnesses and its influencing factors across different cultures. BACKGROUND: The high social and economic burden of neuropsychiatric disorders may be further compounded by stigma. A previous study in a Hispanic community evaluating prevalence and variables associated with stigma is now expanded to study and compare results with two populations in the United States. DESIGN/METHODS: One population from Nicaragua and two from Nebraska were assessed. Participants were asked to view three videos, depicting epilepsy, schizophrenia, and dystonia. Each video was followed by a short questionnaire assessing stigma. Participants were then given additional information about the patient with dystonia and the questionnaire was repeated. Statistical analysis used Exact Chi-square, McNemar test, and more complex logistic regression models. Significance was established by a p<0.05. RESULTS: 273 participants (65.9% female) from three sites: a community health center in Leon, Nicaragua (92 participants), OneWorld Community Health Center in Omaha, Nebraska (85 participants, predominantly Hispanic), and Clarkson West Family Medicine Clinic in Omaha, Nebraska (96 participants, mostly non-Hispanic). Many variables were assessed including age, gender, location, level of education, and ethnic background. The results showed a complex relationship between these variables and level of stigma. Prevalence of stigma was alarming, with 50-to-90% of responses showing some degree of prejudice against neuropsychiatric disorders. Overall, significant differences existed between the three populations, with only minor differences between various ages and genders. Learning more about the people in the videos decreased stigma (p<0.01), a proof that unjustified preliminary harsh judgment is common. CONCLUSIONS: Stigma toward neuropsychiatric disorders is alarmingly common across all three communities studied. Age, gender, and level of education did not correspond to differences in prejudice, underlying the complexity of this problem. More studies are needed to evaluate the true implications of stigma toward neuropsychiatric diseases. Study Supported by: Carole Davis Memorial Fund Disclosure: Dr. Gharzai has nothing to disclose. Dr. Harney has nothing to disclose. Dr. Higgins has nothing to disclose. Dr. High has nothing to disclose. Dr. Xu has nothing to disclose. Dr. Reynolds has nothing to disclose. Dr. Inciarte has nothing to disclose. Dr. Torres-Russotto has received personal compensation for activities with the American Parkinson Disease Foundation, Lundbeck, Teva Neuroscience, Huntington Disease Society of America, Parkinson Disease Foundation, and Merz Pharma.

Counterpoint. Early Intervention for Psychosis Risk Syndromes: Minimizing Risk and Maximizing Benefit

Neuroanatomical Heterogeneity and Homogeneity in Individuals at Clinical High Risk for Psychosis

Parsing stigma's relationship with the psychosocial functioning of youth identified as at clinical high risk for psychosis: evaluating whether symptom stigma or labelling stigma is stronger

The clinical characterization of the patient with primary psychosis aimed at personalization of management

Clinical High-Risk for Psychosis (CHR-P) circa 2024: Synoptic analysis and synthesis of contemporary treatment guidelines

Negative Symptom Trajectories in Individuals at Clinical High Risk for Psychosis: Differences Based on Deficit Syndrome, Persistence, and Transition Status

Gender-affirming care in the assessment and treatment of psychosis risk: Considering minority stress in current practice and future research

Harmonizing early intervention strategies: scoping review of clinical high risk for psychosis and borderline personality disorder

Public stigma associated with psychosis risk syndrome in a college population: implications for peer intervention.

Individualized pretest risk estimates to guide treatment decisions in patients with clinical high risk for psychotic disorders

Antipsychotic Treatment in People at Clinical High Risk for Psychosis: A Narrative Review of Suggestions for Clinical Practice

Psychosis Risk Syndrome is Not Prodromal Psychosis

Reimagining psychoses: an agnostic approach to diagnosis.

Advances in clinical staging, early intervention, and the prevention of psychosis

Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis

Emotional and behavioral symptomatology reported by help-seeking youth at clinical high-risk for psychosis

Efficacy and Acceptability of Interventions for Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of Psychosis: A Network Meta-Analysis

Psychiatric diagnosis and treatment in the 21st century: paradigm shifts versus incremental integration

Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study

Cross-Cultural Comparison of Stigma Toward Mental and Neurological Disorders (P6.002)

Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study